{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:50:58Z","timestamp":1791640258558,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["# U24AG057437"],"award-info":[{"award-number":["# U24AG057437"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This article summarizes the architecture, design principles, and implementation strategy of the ATRI Laboratory Information Management System (LIMS), a cloud\u2011native, open\u2011source platform supporting biomarker\u2011driven Alzheimer\u2019s disease (AD) clinical research. The system addresses challenges associated with managing large\u2011scale, multimodal biomarker, and biobanking data across multisite studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ATRI LIMS employs a Model\u2013View\u2013Controller architecture implemented in Django, with Single\u2011Page Application interfaces built in ReactJS. A hybrid database model integrates a normalized core schema with study\u2011specific extensions. Deployment on Amazon Web Services incorporates multifactor authentication, encryption, and a web application firewall. Regulatory support is provided through audit trails and electronic signatures. Development relied on collaboration between informatics engineers and laboratory personnel, with user acceptance testing guiding workflow and interface refinement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of February 2026, the ATRI LIMS supports seven clinical trials and observational studies and manages more than 1.2 million biospecimens. The platform synchronizes biospecimen metadata and assay outputs with clinical datasets, improves operational efficiency through automated workflows and quality control, and facilitates compliant sample sharing for secondary research. AI\u2011assisted development accelerated feature delivery while maintaining code quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The ATRI LIMS offers a scalable, adaptable informatics framework for biomarker\u2011intensive AD research. Its modular design, cloud\u2011native architecture, and comprehensive data management capabilities support accurate specimen tracking and coordinated data integration. An open-source release is planned to enable adoption and adaptation by other research programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ATRI LIMS enhances informatics infrastructure for modern AD research by enabling scalable, efficient, and compliant biomarker and biospecimen workflow management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jamiaopen\/ooag198","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:26:20Z","timestamp":1790335580000},"source":"Crossref","is-referenced-by-count":0,"title":["ATRI LIMS: a cloud-native open-source laboratory information management system for biomarker-driven Alzheimer\u2019s disease clinical trials"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-5121","authenticated-orcid":false,"given":"Gustavo A","family":"Jimenez-Maggiora","sequence":"first","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bruschi","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abdel-Latif","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Aisen","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Rissman","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"2026101009051394900_ooag198-B1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s Dement"},{"key":"2026101009051394900_ooag198-B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2026101009051394900_ooag198-B3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2026101009051394900_ooag198-B4","doi-asserted-by":"publisher","first-page":"e70662","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: screening and baseline data from TRAILBLAZER-ALZ 3","volume":"21","author":"Yaari","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026101009051394900_ooag198-B5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer\u2019s Dement"},{"key":"2026101009051394900_ooag198-B6","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026101009051394900_ooag198-B7","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2026101009051394900_ooag198-B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026101009051394900_ooag198-B9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"key":"2026101009051394900_ooag198-B10","first-page":"S13","article-title":"A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease","volume":"10","author":"Rissman","year":"2023","journal-title":"J Prevent Alzheimer\u2019s Dis"},{"key":"2026101009051394900_ooag198-B11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026101009051394900_ooag198-B12","author":"Epstein ATRI","year":"2025"},{"key":"2026101009051394900_ooag198-B13","author":"Neuroscience translational research division - Epstein ATRI","year":"2024"},{"key":"2026101009051394900_ooag198-B14","author":"Informatics-Alzheimer\u2019s Therapeutic Research Institute","year":"2023"},{"key":"2026101009051394900_ooag198-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14283\/jpad.2020.48","article-title":"Trc-pad: accelerating recruitment of AD clinical trials through innovative information technology","author":"Jimenez-Maggiora","year":"2020","journal-title":"J Prevent Alzheimer\u2019s Dis"},{"key":"2026101009051394900_ooag198-B16","doi-asserted-by":"publisher","first-page":"ooab119","DOI":"10.1093\/jamiaopen\/ooab119","article-title":"ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer\u2019s disease and Alzheimer\u2019s disease-related dementias clinical trials","volume":"5","author":"Jimenez-Maggiora","year":"2022","journal-title":"JAMIA Open"},{"key":"2026101009051394900_ooag198-B17","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.tjpad.2024.100002","article-title":"Artificial intelligence-enabled safety monitoring in Alzheimer\u2019s disease clinical trials","volume":"12","author":"Jimenez-Maggiora","year":"2025","journal-title":"The Journal of Prevention of Alzheimer\u2019s Dis"},{"key":"2026101009051394900_ooag198-B18","author":"Bruschi","year":"2019"},{"key":"2026101009051394900_ooag198-B19","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.120","article-title":"Maximizing the utility of Alzheimer\u2019s disease trial data: sharing of baseline A4 and LEARN data","author":"Jimenez-Maggiora","year":"2024","journal-title":"J Prevent Alzheimer\u2019s Dis"},{"key":"2026101009051394900_ooag198-B20","author":"Center for Drug Evaluation and Research, U.S. Food & Drug Administration","year":"2025"}],"container-title":["JAMIA Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/9\/5\/ooag198\/71837606\/ooag198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/9\/5\/ooag198\/71837606\/ooag198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:05:17Z","timestamp":1791637517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article\/doi\/10.1093\/jamiaopen\/ooag198\/8907261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jamiaopen\/ooag198","relation":{},"ISSN":["2574-2531"],"issn-type":[{"value":"2574-2531","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"ooag198"}}